Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Introduction: Research on diagnostic and biomarker disclosure has significantly increased, particularly in the field of Alzheimer's disease (AD). The psychological impact of learning amyloid positron emission tomography (PET) results has been frequently assessed using the Impact of Genetic Testing for Alzheimer's Disease (IGT-AD) instrument. Establishing an optimal cutoff score for this screening tool is essential for efficiently identifying individuals who may require psychological support after amyloid PET disclosure. In this study, we aimed to determine the optimal distress cutoff for the adapted IGT-AD instrument after amyloid PET result disclosure in cognitively symptomatic older adults.

Methods: We adapted the IGT-AD instrument by replacing reference to genetic testing with reference to amyloid PET testing. A total of 98 participants with either mild cognitive impairment (MCI) or dementia were assessed for psychological impact using this adapted instrument and the Impact of Event Scale (IES; cutoff = 26) as a gold standard. Receiver operating characteristic analysis determined the optimal distress cutoff, with the Youden index maximizing sensitivity and specificity. The area under the curve (AUC) was calculated to evaluate the predictive accuracy of the IGT-AD.

Results: The mean age of participants was 72.6 years, 41.8% were male, 77.6% were White, 16.3% were Black, and 15.3% were of Hispanic ethnicity. Most (57.2%) held bachelor or post-bachelor degrees, and 73.5% were married or cohabiting. The optimal cutoff point for the modified IGT-AD Distress subscale was determined to be 15, with a sensitivity of 100% and specificity of 70.1%. The AUC for distress was 0.89 (95% confidence interval: 0.82-0.95), indicating good predictive power.

Discussion: A distress score ≥ 15 on the adapted IGT-AD appears to be a suitable cutoff for detecting significant psychological distress in cognitively symptomatic individuals learning their amyloid PET result. This cutoff has potential clinical and research applications for screening and early intervention.

Highlights: The Impact of Genetic Testing for Alzheimer's Disease (IGT-AD) instrument is widely used to assess the psychological impact of Alzheimer's disease biomarker disclosure.Establishing a cutoff score is essential for identifying individuals needing psychological support.Receiver operating characteristic analysis determined the optimal IGT-AD distress cutoff, using Impact of Event Scale (cutoff = 26) as the gold standard.The optimal cutoff for moderate to severe distress on the adapted IGT-AD is 15.Larger studies are needed to validate this cutoff.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12144969PMC
http://dx.doi.org/10.1002/trc2.70116DOI Listing

Publication Analysis

Top Keywords

amyloid pet
20
optimal cutoff
16
alzheimer's disease
16
igt-ad instrument
16
adapted igt-ad
16
igt-ad distress
12
psychological impact
12
genetic testing
12
distress cutoff
12
cutoff
11

Similar Publications

Peripheral Inflammation Is Associated With Greater Neuronal Injury and Lower Episodic Memory Among Late Middle-Aged Adults.

J Neurochem

September 2025

Division of Neurogeriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.

Elucidating the earliest biological mechanisms underlying Alzheimer's disease (AD) is critical for advancing early detection strategies. While amyloid-β (Aβ) and tau pathologies have been central to preclinical AD research, the roles of peripheral biological processes in disease initiation remain underexplored. We investigated patterns of F-MK6240 tau positron emission tomography (PET) and peripheral inflammation across stages defined by Aβ burden and neuronal injury in n = 132 (64.

View Article and Find Full Text PDF

Systemic amyloidosis is a complex disorder, making early and accurate diagnosis challenging. The most common types are associated with misfolded transthyretin or immunoglobulin light chains, where cardiac and renal amyloidosis portend the worst prognosis. Peptide p5+14 can bind all types of amyloid via multivalent electrostatic interactions.

View Article and Find Full Text PDF

The distribution of tau pathology in Alzheimer's disease (AD) shows remarkable inter-individual heterogeneity, including hemispheric asymmetry. However, the factors driving this asymmetry remain poorly understood. Here we explore whether tau asymmetry is linked to i) reduced inter-hemispheric brain connectivity (potentially restricting tau spread), or ii) asymmetry in amyloid-beta (Aβ) distribution (indicating greater hemisphere-specific vulnerability to AD pathology).

View Article and Find Full Text PDF

Introduction: Glial fibrillary acidic protein (GFAP) may contribute to Alzheimer's pathology at early disease stages. GFAP moderation of Alzheimer's disease (AD)-related neurodegeneration and cognition is unclear.

Methods: We examined plasma GFAP moderation of AD biomarkers (amyloid beta [Aβ]-positron emission tomography [PET][A]; plasma phosphorylated tau-181 [p-tau181][T]), neurodegeneration (plasma NfL[N]; structural magnetic resonance imaging [MRI][N]), and cognition (Cog; Cog) in two cohorts: University of California San Francisco (UCSF) (N = 212, 91.

View Article and Find Full Text PDF

Background: Disease-modifying therapies with amyloid-antibodies will soon be available for patients with early Alzheimer's disease, which necessitates diagnostic and therapeutic resources in hospital and outpatient settings.

Methods: The Austrian Alzheimer Society developed an online questionnaire to survey Austrian hospital-based departments of neurology and psychiatry regarding resources for amyloid-antibody therapies.

Results: Between May and October 2023, 30 out of 41 neurology (73%) and 12 out of 33 psychiatry departments (36%) responded.

View Article and Find Full Text PDF